Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Prospect Capital Corporation (PSEC) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

Prospect Capital CorporationTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Prospect Capital Corporation vs Health Care Select Sector SPDR Fund — how do they compare? Prospect Capital Corporation trades at $2.14 (market cap $1.08B), while Health Care Select Sector SPDR Fund trades at $159.56. The key difference: Prospect Capital Corporation pays a 23.26% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Prospect Capital Corporation nearer its low. Which is the better fit depends on your goals.

PSECXLV
Market Cap
$1.08B
Sector
Financials
52-Week High
$3.47$164.48
52-Week Low
$2.15$129.01
Dividend Yield
23.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Prospect Capital Corporation

Prospect Capital Corporation (PSEC) trades at $2.15, down 4.44% on the day, reflecting persistent bearish technical signals. The company's fundamentals are challenged, with negative revenue of -$407M and a net income margin of -495.94% for 2025, though it has beaten EPS estimates for the last three consecutive quarters. Recent corporate actions include regular dividend payments, while news highlights portfolio activity and deep discounts to net asset value.

The outlook remains cautious due to weak profitability and a bearish analyst consensus. The primary opportunity lies in the stock's high yield and significant discount to book value, but risks include ongoing revenue volatility, declining net asset value, and skepticism about portfolio quality. Investors should weigh income potential against fundamental deterioration.

Health Care Select Sector SPDR Fund

XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.

XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

Read more on PSEC

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV